Side-by-side comparison of AI visibility scores, market position, and capabilities
Lausanne Switzerland automated cloud lab for AI protein engineering at $11.2M total ($8M ACE Ventures seed 2025); improved protein success rate from 2.
Adaptyv Biosystems is a Lausanne, Switzerland-based AI-driven protein engineering platform — backed with $11.2 million in total funding including an $8 million seed round in 2025 led by ACE Ventures with participation from ByFounders, Founderful, and LongGame Ventures, following a CHF 2.5 million pre-seed in 2022 — providing pharmaceutical companies, biotechnology firms, and academic AI research groups with fully automated cloud laboratory services for validating and iterating AI-generated protein designs, enabling the experimental testing that transforms computational protein engineering from theoretical exploration to practical drug discovery. Founded in 2021 and having tested over 10,000 proteins in collaboration with 30+ pharma and biotech partners, Adaptyv has improved protein engineering success rates from the industry baseline of 2.5% to 13% — a 5x improvement that represents the breakthrough enabling practical AI-guided therapeutic protein development.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.